Home Itens selecionados Provedores de dados OAI Créditos Sobre Ajuda

			Busca avançada
	Provedor de dados BJID (1) Autor Crespo,Déborah (1) Nascimento,Yone de Almeida (1) Teixeira,Rosângela (1) Palavra-chave Adverse events (1) Drug interactions (1) Hepatitis C (1) Protease inhibitors (1) Tipo do documento Info:eu-repo/semantics/article (1) Ano 2013 (1) País Brazil (1) Idioma Inglês (1)		Ordenar por:  Relevância Autor Título Ano Registros recuperados: 1 Primeira ... 1 ... Última Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions BJID Teixeira,Rosângela; Nascimento,Yone de Almeida; Crespo,Déborah. The standard of care therapy of chronic hepatitis C with the combination of pegylated interferon and ribavirin for 24 or 48 weeks was a remarkable accomplishment of the past decade. However, sustained virological responses rates of about 80% (genotypes 2-3) and 50% (geno 3 type 1) were not satisfactory especially for patients infected with genotype 1. Important advances in the biology of HCV have made possible the development of the direct-acting antiviral agents boceprevir and telaprevir with substantial increase in the rates of sustained virological response with shorter duration of therapy for a large number of patients. However, the complexity of triple therapy is higher and several new side effects are expected suggesting greater expertise in the... Tipo: Info:eu-repo/semantics/article Palavras-chave: Hepatitis C; Protease inhibitors; Adverse events; Drug interactions. Ano: 2013 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702013000200013 Registros recuperados: 1 Primeira ... 1 ... Última

Empresa Brasileira de Pesquisa Agropecuária - Embrapa Todos os direitos reservados, conforme Lei n° 9.610 Política de Privacidade Área restrita		Embrapa Parque Estação Biológica - PqEB s/n° Brasília, DF - Brasil - CEP 70770-901 Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco